The estimated Net Worth of James E Deerfield Mgmt L.P.... is at least $36.4 Milion dollars as of 28 September 2015. James P owns over 1,828,529 units of Antares Pharma Inc stock worth over $29,899,658 and over the last 9 years James sold ATRS stock worth over $6,546,134.
James has made over 2 trades of the Antares Pharma Inc stock since 2015, according to the Form 4 filled with the SEC. Most recently James sold 1,828,529 units of ATRS stock worth $3,273,067 on 28 September 2015.
The largest trade James's ever made was selling 1,828,529 units of Antares Pharma Inc stock on 28 September 2015 worth over $3,273,067. On average, James trades about 1,828,529 units every 0 days since 2015. As of 28 September 2015 James still owns at least 5,348,776 units of Antares Pharma Inc stock.
You can see the complete history of James P stock trades at the bottom of the page.
Over the last 12 years, insiders at Antares Pharma Inc have traded over $29,755,747 worth of Antares Pharma Inc stock and bought 910,400 units worth $1,278,090 . The most active insiders traders include James E Deerfield Mgmt L.P...., James E Deerfield Mgmt L.P.... oraz Jacques Gonella. On average, Antares Pharma Inc executives and independent directors trade stock every 28 days with the average trade being worth of $751,296. The most recent stock trade was executed by Anton Gueth on 8 July 2021, trading 100,000 units of ATRS stock currently worth $429,000.
Antares Pharma, Inc. is a pharmaceutical technology company focused primarily on the development and commercialization of self-administered injectable pharmaceutical products using advanced drug delivery auto injector technology. The Company has a portfolio of proprietary and partnered commercial products with several product candidates in various stages of development, as well as significant strategic alliances with industry leading pharmaceutical companies including Teva Pharmaceutical Industries, Ltd. (Teva), Covis Pharma (Covis), Pfizer Inc. (Pfizer) and Idorsia Pharmaceuticals Ltd. (Idorsia). Antares Pharma's FDA-approved products include XYOSTED® (testosterone enanthate) injection, OTREXUP® (methotrexate) injection for subcutaneous use and Sumatriptan Injection USP, which is distributed by Teva. The Company also markets NOCDURNA® (desmopressin acetate) in the U.S., which was licensed from Ferring Pharmaceuticals.
Antares Pharma Inc executives and other stock owners filed with the SEC include: